An experience of terlipressin therapy for patients with hepatorenal syndrome
-
- Narahara Yoshiyuki
- Department of Internal Medicine, Division of Gastroenterology, Nippon Medical School
-
- Kanazawa Hidenori
- Department of Internal Medicine, Division of Gastroenterology, Nippon Medical School
-
- Fukuda Takeshi
- Department of Internal Medicine, Division of Gastroenterology, Nippon Medical School
-
- Harimoto Hirotomo
- Department of Internal Medicine, Division of Gastroenterology, Nippon Medical School
-
- Matsushita Yoko
- Department of Internal Medicine, Division of Gastroenterology, Nippon Medical School
-
- Kidokoro Hideko
- Department of Internal Medicine, Division of Gastroenterology, Nippon Medical School
-
- Katakura Tamaki
- Department of Internal Medicine, Division of Gastroenterology, Nippon Medical School
-
- Atsukawa Masanori
- Department of Internal Medicine, Division of Gastroenterology, Nippon Medical School
-
- Taki Yasuhiko
- Department of Internal Medicine, Division of Gastroenterology, Nippon Medical School
-
- Kimura Yuu
- Department of Internal Medicine, Division of Gastroenterology, Nippon Medical School
-
- Nakatsuka Katsuhisa
- Department of Internal Medicine, Division of Gastroenterology, Nippon Medical School
-
- Sakamoto Choitsu
- Department of Internal Medicine, Division of Gastroenterology, Nippon Medical School
Bibliographic Information
- Other Title
-
- 肝腎症候群に対するterlipressinによる治療経験
Search this article
Abstract
Effect of terlipressin on hepatorenal syndrome was investigated in 8 patients with liver cirrhosis. Terlipressin (1-3 mg/day) and albumin (12.5-37.5 g/day) were administered for a mean period of 4 days (1-14 days). Urine volume, urine sodium excretion, and creatinine clearance increased significantly [from 834 ± 541 to 1182 ± 664 ml (p = 0.04), from 24.7 ± 17.4 mEq/day to 51.7 ± 38.7 mEq/day (p = 0.01), and from 14.5 ± 7.6 ml/min to 28 ± 16.2 ml/min (p = 0.03), respectively], while serum creatinine level and plasma renin activity fell significantly [from 2.43 ± 0.75 mg/dl to 1.81 ±± 0.72 mg/dl (p = 0.03) and 8.6 ± 7.9 ng/ml/hr to 5.1 ± 6.6 ng/ml/hr (p = 0.03), respectively] after the treatment. Diarrhea and abdominal cramp events were seen in 5 and 3 patients, respectively, during the treatment, and they required reduction of the dose of terlipressin in 1 patient and discontinuation of the treatment in 1 patient. These results suggest that terlipressin, together with albumin, safely and effectively improves hepatorenal syndrome by increasing effective arterial blood volume and glomerular filtration rate.
Journal
-
- Japanese Journal of Portal Hypertension
-
Japanese Journal of Portal Hypertension 12 (4), 285-290, 2006
The Japan Society for Portal Hypertension
- Tweet
Details 詳細情報について
-
- CRID
- 1390282680433677696
-
- NII Article ID
- 130004989511
-
- ISSN
- 13448447
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- CiNii Articles
-
- Abstract License Flag
- Disallowed